TAS-102
- Generic Name
- TAS-102
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 733030-01-8
- Unique Ingredient Identifier
- -
- Background
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trif...
- Indication
用于治疗曾经接受氟嘧啶，奥沙利铂和伊立替康为基础的化疗，抗VEGF生物治疗和抗EGFR治疗（如果是RAS野生型）无效的转移性结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02301104
- Locations
- 🇺🇸
Dallas Clinical Site, Dallas, Texas, United States
🇺🇸Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, United States
🇺🇸Cleveland Clinical Site, Cleveland, Ohio, United States
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Registration Number
- NCT02286492
- Locations
- 🇺🇸
The Mark H. Zangmeister Center, Columbus, Ohio, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Phase I Study of TAS-102 in Solid Tumors
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02261532
- Locations
- 🇨🇳
Taiho Pharmaceutical Co., Ltd selected site, Beijing, China
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 406
- Registration Number
- NCT01955837
- Locations
- 🇹🇭
Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇨🇳Peking University Cancer Hospital, Beijing, China
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01916447
- Locations
- 🇺🇸
Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Chicago Clinical Site, Chicago, Illinois, United States
🇺🇸Los Angeles Clinical Site, Los Angeles, California, United States
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01904253
- Locations
- 🇯🇵
National Cancer Center Hospital East, Chiba, Japan
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
🇯🇵Hyogo Cancer Center, Hyogo, Japan
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-10-06
- Target Recruit Count
- 118
- Registration Number
- NCT01896856
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01867866
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01867879
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT01607957
- Locations
- 🇺🇸
San Jose Medical Group, San Jose, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Jefferson City Medical Group, Jefferson City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.